title: Supporting malaria elimination with 21st century antimalarial agent drug discovery.
abstract: The burden of malaria has been considerably reduced over recent years. However, to achieve disease elimination, drug discovery for the next generation needs to focus on blocking disease transmission and on targeting the liver-stage forms of the parasite. Properties of the 'ideal' new antimalarial drug and the key scientific and technological advances that have led to recent progress in antimalarial drug discovery are reviewed. Using these advances, Novartis has built a robust pipeline of next-generation antimalarials. The preclinical and clinical development of two candidate drugs: KAE609 and KAF156, provide a framework for the path to breakthrough treatments that could be taking us a step closer to the vision of malaria elimination.
authors.affiliation: Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore 138670, Singapore. Electronic address: thierry.diagana@novartis.com.
authors.forename: Thierry T
authors.initials: TT
authors.lastname: Diagana
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000494:pharmacology; D015195:Drug Design; D055808:Drug Discovery; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D013141:Spiro Compounds / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000962:Antimalarials; D007093:Imidazoles; D007211:Indoles; C552304:NITD 609; D010879:Piperazines; D013141:Spiro Compounds; C000599914:ganaplacide